Firm on lookout for 'opportunities'
Craneware bullish as sales surge in US
The Edinburgh based group expects a 15% increase in both revenue and adjusted EBITDA for the six month to the end of December.
This builds on the return to double digit growth reported in the year to 30 June and slightly ahead of expectations.
Underlying sales continue to support this growth, with a particularly strong Q2, post the US Election result, and a healthy sales pipeline.
The group continues to invest for the future. In the period it has invested c$3m in its newly formed Employee Benefit trust and over $1 million in future product development.
It is continuing a progressive dividend payment policy and has a $50m war chest as it continues to investigate “strategic opportunities”.
The board said it is confident in meeting market expectations for the full year. It will announce its interim figures on 7 March.
Keith Neilson (pictured), chief executive, said: “There is continued consensus in the US of the need to drive value in healthcare with ongoing support for the move to value-based care and increasing consumerism.”
He said it a “particularly pleasing” to see sales increase at a time of change in Washington.
“We continue to invest in both our current solutions and in the new products we are developing to expand our support to US Healthcare providers as they pursue quality patient outcomes and optimal financial performance.
“These supportive market drivers, our investment for the future and our continued profitable growth, give management confidence in its ability to deliver continued stakeholder value.”